Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Entinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC3 known ✓ | O15379 | 11/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 11/20 | 1.00 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 9/20 | 1.00 |
| ▸ | HDAC4 known ✓ | P56524 | 8/20 | 1.00 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 8/20 | 1.00 |
| ▸ | HDAC10 known ✓ | Q969S8 | 8/20 | 1.00 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 8/20 | 1.00 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 8/20 | 1.00 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 8/20 | 1.00 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 8/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | F3 | P13726 | 1/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | NAMPT | P43490 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Entinostat SCHEMBL29838042 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL29387345 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL29499905 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2407986 | 0.99 | HDAC1 (0.98) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2409897 | 0.99 | HDAC1 (0.98) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2412431 | 0.97 | HDAC1 (0.94) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2412014 | 0.96 | HDAC1 (0.93) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2413749 | 0.96 | HDAC1 (0.93) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL2415852 | 0.96 | HDAC1 (0.92) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2408179 | 0.95 | HDAC1 (0.91) | HDAC1HDAC3HDAC2HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7357 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637498-B2 | PDLIM2 as a biomarker for cancer and as an anti-cancer treatment target | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-05-26 | — | — | US | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122075711-A | Application of histone deacetylase inhibitor HDACi in preparation of medicines for preventing and/or treating ammonia-induced encephalopathy | — | 2026-05-26 | — | — | CN | claimed |
| CN-122070932-A | Application of combination of decitabine and anti-HER 2 antibody in preparation of medicines for treating tumors | 上海交通大学 | 2026-05-22 | — | — | CN | claimed |
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3429570-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | ORYZON GENOMICS SA (ES) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102034-A1 | COMPOSITIONS AND METHODS FOR GENETIC AND EPIGENETIC MODULATION | JUNIPERO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2026101232-A1 | POLYMER COMPOUND FOR CELL SURFACE MODIFICATION FOR IMPROVING DRUG DELIVERY EFFICIENCY | 동국대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| WO-2007041071-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. (US) | 2007-04-12 | — | — | WO | claimed |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | ASTEX PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | claimed |
| WO-2007022044-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | claimed |
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | claimed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | claimed |
| US-20050215601-A1 | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-09-29 | — | — | US | claimed |
| EP-1547585-A1 | THERAPEUTIC AGENT FOR RHEUMATISM CONTAINING BENZAMIDE DERIVATIVE AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | claimed |
| US-6905669-B2 | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase | SUPERGEN, INC. (US) | 2005-06-14 | — | — | US | claimed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | claimed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | claimed |